Aprotinin

• Description:

  Aprotinin is a bovine pancreatic trypsin inhibitor (BPTI) inhibitor which inhibits trypsin and chymotrypsin with Kis of 0.06 pM and 9 nM, respectively.

• UNSPSC:

  12352209

• Hazard Statement:

  H315, H319, H335

• Target:

  Influenza Virus; Ser/Thr Protease

• Type:

  Natural Products

• Related Pathways:

  Anti-infection; Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Aprotinin.html

• Purity:

  99.01

• Solubility:

  H2O : 100 mg/mL (ultrasonic)

• Smiles:

  O=C (N1[C@@H] (CCC1) C (N[C@@H] (CC (O) =O) C (N[C@@H] (CC2=CC=CC=C2) C (N[C@@H] (CSSC[C@@H] (C (NCC (NCC (N[C@@H] (C) C (O) =O) =O) =O) =O) NC3=O) C (N[C@@H] (CC (C) C) C (N[C@@H] (CCC (O) =O) C (N4[C@@H] (CCC4) C (N5[C@@H] (CCC5) C (N[C@@H] (CC6=CC=C (C=C6) O) C (N[C@@H] ([C@H] (O) C) C (NCC (N7[C@@H] (CCC7) C (N[C@@H] (CSSC[C@@H] (C (N[C@H] (CCCNC (N) =N) C (N[C@@H] (C) C (N[C@@H] (CCCCN) C (N[C@@H] (CCCNC (N) =N) C (N[C@@H] (CC (N) =O) C (N[C@@H] (CC (N) =O) C (N[C@@H] (CC8=CC=CC=C8) C (N[C@@H] (CCCCN) C (N[C@@H] (CO) C (N[C@@H] (C) C (N[C@@H] (CCC (O) =O) C (N[C@H]9CC (O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) NC%10=O) C (N[C@@H] (CCCCN) C (N[C@@H] (C) C (N[C@@H] (CCCNC (N) =N) C (N[C@@H] ([C@@H] (C) CC) C (N[C@@H] ([C@@H] (C) CC) C (N[C@@H] (CCCNC (N) =N) C (N[C@@H] (CC%11=CC=C (C=C%11) O) C (N[C@@H] (CC%12=CC=CC=C%12) C (N[C@@H] (CC%13=CC=C (C=C%13) O) C (N[C@@H] (CC (N) =O) C (N[C@@H] (C) C (N[C@@H] (CCCCN) C (N[C@@H] (C) C (NCC (N[C@@H] (CC (C) C) C (N[C@@H] (CSSC[C@@H] (C (N[C@@H] (CCSC) C (N[C@@H] (CCCNC (N) =N) C (N[C@H]3[C@H] (O) C) =O) =O) =O) NC9=O) C (N[C@@H] (CCC (N) =O) C (N[C@@H] ([C@H] (O) C) C (N[C@@H] (CC%14=CC=CC=C%14) C (N[C@@H] (C (C) C) C (N[C@@H] (CC%15=CC=C (C=C%15) O) C (NCC (NC%10) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) [C@H] (CCCNC (N) =N) N

• Molecular Formula:

  C284H432N84O79S7

• Molecular Weight:

  6511.44

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Fritz H, et al. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung. 1983;33 (4) :479-94.|[2]Levy JH, et al. Efficacy and safety of aprotinin in cardiac surgery. Orthopedics. 2004 Jun;27 (6 Suppl) :s659-62.|[3]Venturini G, et al. Aprotinin, the first competitive protein inhibitor of NOS activity. Biochem Biophys Res Commun. 1998 Aug 10;249 (1) :263-5|[4]Sperzel M, et al. Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5 (10) :2113-8. Epub 2007 Jul 31.|[5]Davis R, et al. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated withcardiac surgery. Drugs. 1995 Jun;49 (6) :954-83.|[6]Sabbagh MJ, et al. Aprotinin exacerbates left ventricular dysfunction after ischemia/reperfusion in mice lacking tumor necrosis factor receptor I. J Cardiovasc Pharmacol. 2008 Oct;52 (4) :355-62.|[7]Levy JH, et al. Efficacy and safety of aprotinin in cardiac surgery. Orthopedics. 2004 Jun;27 (6 Suppl) :s659-62.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  Store at -20°C for 2 years

• Scientific Category:

  Natural Products

• Clinical Information:

  Launched

• CAS Number:

  9087-70-1